PT-141
Price range: $70.00 through $193.99
- Raw ingredients manufactured by a federally regulated & audited labratory
- Packaged in a GMP (Good Manufacturing Practices) facility
- Third party testing conducted by a federally audited, ISO certified analytical lab
- Sterility guaranteed
- LPS & endotoxin free
- Greater than 99% pure
PT-141 (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH) is a cyclic heptapeptide melanocortin agonist engineered for high MC-4 / MC-3 receptor selectivity and blood–brain-barrier permeability. Pre-clinical models and late-stage trials demonstrate centrally mediated increases in sexual arousal, libido, and penile tumescence independent of the nitric-oxide pathway, with transient blood-pressure elevations as the principal dose-limiting effect. Additional rodent data point to reward-circuit modulation, anti-inflammatory signaling, and analgesic potential via melanocortin-driven cytokine balance.
| Quantity | 10mg*10vials |
|---|
Be the first to review “PT-141”
Related products
Price range: $30.00 through $119.00
This product has multiple variants. The options may be chosen on the product page
Sale!
PEPTIDES
Price range: $50.00 through $109.00
This product has multiple variants. The options may be chosen on the product page
PEPTIDES
Price range: $95.00 through $189.00
This product has multiple variants. The options may be chosen on the product page
PEPTIDES
Price range: $50.00 through $90.00
This product has multiple variants. The options may be chosen on the product page
PEPTIDES
Price range: $55.00 through $155.00
This product has multiple variants. The options may be chosen on the product page
PEPTIDES
Price range: $79.99 through $140.00
This product has multiple variants. The options may be chosen on the product page
PEPTIDES
Price range: $60.00 through $88.00
This product has multiple variants. The options may be chosen on the product page
PEPTIDES
Price range: $80.00 through $262.00
This product has multiple variants. The options may be chosen on the product page
Reviews
There are no reviews yet.